Home > Journals > Minerva Pneumologica > Past Issues > Minerva Pneumologica 2005 December;44(4) > Minerva Pneumologica 2005 December;44(4):179-96

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS   

Minerva Pneumologica 2005 December;44(4):179-96

Copyright © 2005 EDIZIONI MINERVA MEDICA

language: English

Gene therapy of lung cancer. Experimental approaches and clinical relevance

Kuhn H., Hammerschmidt S., Wirtz H.


PDF


Lung cancer accounts for a considerable part of cancer mortality worldwide. The poor prognosis of patients with advanced stage lung cancer in response to conventional therapies, i.e. chemotherapy and radiotherapy, demands novel therapeutic approaches. Gene therapy constitutes a novel strategy. A better understanding of mechanisms involved in lung cancer pathogenesis and improved molecular biology techniques led to a growing number of approaches involving gene therapy. These approaches include replacement of tumor suppressor genes, introducing of suicide genes, inhibition of anti-apoptotic pathways, inactivation of oncogenes, inhibition of tumor angiogenesis and invasion, and the improvement of anticancer immune response. The clinical implementation of these approaches is limited by problems including gene transfer efficiency, non-specific toxicity and host immune response. This article presents an update on experimental results and their clinical application and limitation within the field of lung cancer gene therapy.

top of page